金凯生科 (301509)

Kingchem (Liaoning) Life Science Co., Ltd.

ASZ

Tags

Contract Research Organization (CXO)Specialized-Sophisticated-Distinctive-Innovative EnterprisesWeight Loss DrugsMedical ServicesPlanned Reduction of HoldingsFluorine ConceptBelow IPO PriceHigh-Performing StocksMargin Trading and Securities LendingChiNext Small CapShenzhen Recently Listed StocksCSI 2000 IndexSZSE Medicine Equal Weight IndexCSI Circulation IndexCSI All-share IndexShenzhen A-Share Pharmaceutical IndexChiNext Composite IndexCSI All-share Pharmaceutical Sector IndexExpected Loss/DeclineQFII HoldingsFund Heavy HoldingsExpected Profit/IncreaseCNI 2000 IndexSZSE Composite IndexNew IndexManufacturing IndexCSI A-Share IndexCNI A-Share IndexLiaoning

K-Line Chart

No K-line data available

Company NameJinkai (Liaoning) Life Sciences Co., Ltd.
Listing Date2023-08-03
Issue Price56.56RMB
Registered Capital12044.666910k RMB
Legal RepresentativeFumin Wang
Registered AddressNo. 6 Anren Road, Fluorochemical Industrial Park, Yimatu Town, Fumeng County, Fuxin City, Liaoning Province, China
IndustryMedical Services
Main BusinessA small-molecule CDMO service provider serving global clients in the life sciences sector, offering custom R&D and production services for small-molecule drug intermediates and a small amount of active pharmaceutical ingredients (APIs) for new drug development projects of globally renowned innovative pharmaceutical companies.
Company ProfileJinkai (Liaoning) Life Sciences Co., Ltd. is a small-molecule CDMO service provider serving global clients in the life sciences sector. It provides custom R&D and production services for small-molecule drug intermediates and a small amount of active pharmaceutical ingredients (APIs) for new drug development projects of globally renowned innovative pharmaceutical companies. The company assists these clients in addressing challenges in the innovative drug R&D process, such as process development, process optimization, process scale-up, and large-scale production of compound synthesis, effectively improving the efficiency of new drug R&D for innovative pharmaceutical companies and reducing their R&D and production costs. The company's CDMO services for large multinational pharmaceutical and biopharmaceutical groups, innovative drug companies, and chemical groups involve the deep integration of compound process route R&D and production. Through years of technological innovation and development, the company has developed the capability to independently research and develop process routes for numerous small-molecule compounds, overcome technical bottlenecks in production, and utilize its comprehensive reaction capabilities to ensure the implementation of the developed technical routes.

Stock Details

1. Key Indicators

  • Total Shares(W): 12044.67
  • Circulating A-Shares(W): 5674.09
  • Earnings Per Share(RMB): 0.8600
  • Net Assets Per Share(RMB): 18.3006
  • Operating Revenue(W RMB): 48771.55
  • Total Profit(W RMB): 12013.02
  • Net Profit Attributable to Parent(W RMB): 10342.93
  • Net Profit Growth Rate(%): 163.24
  • Weighted Return on Equity(%): 4.7400
  • Operating Cash Flow Per Share(RMB): 1.2390
  • Undistributed Profit Per Share(RMB): 3.5357
  • Capital Reserve Per Share(RMB): 13.2703

2. Main Business

The main business covers:

  • CDMO business

3. Company Basic Information

  • Company Name: Kingchem (Liaoning) Life Science Co., Ltd.
  • Listing Date: 2023-08-03
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 6 Anren Road, Fluorochemical Industrial Park, Yimatu Town, Fumeng County, Fuxin City, Liaoning Province, China
  • Website: www.kingchemchina.com
  • Company Profile: The issuer was established through the overall change of Kingchem Limited into a joint stock limited company. On September 22, 2020, Ernst & Young Hua Ming issued an audit report, confirming the owner's equity of Kingchem Limited as RMB 300.2144 million as of April 30, 2020. On October 15, 2020, Beijing China Enterprise Appraisal Co., Ltd. issued an asset appraisal report, confirming the net asset appraisal value of Kingchem Limited as RMB 459.9104 million as of April 30, 2020. On November 8, 2020, Kingchem Limited held a temporary board meeting and approved the plan for the overall change into a joint stock limited company. On November 23, 2020, the issuer held the inaugural meeting and the first shareholders' meeting, approving relevant proposals. On November 28, 2020, the Fuxin Market Supervision Administration approved the issuer's overall change into a joint stock limited company and issued the business license.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Qilu (Xiamen) Equity Investment Partnership Enterprise (Limited Partnership) General Legal Person 593.66 10.46
2 Qingdao Qingsong Venture Capital Group Co., Ltd. - Qingdao Songkai Venture Capital Enterprise (Limited Partnership) General Legal Person 386.11 6.80
3 Blue Economic Zone Industrial Investment Fund (Limited Partnership) General Legal Person 233.91 4.12
4 Central Enterprise Rural Industry Investment Fund Co., Ltd. General Legal Person 110.00 1.94
5 Zhuhai Hengqin Zhiben Financial Investment Management Co., Ltd. - Zhiben Tianhong No. 3 Private Securities Investment Fund Private Securities Investment Fund 20.00 0.35

5. Concept Sectors

  • Hydrogen Energy
  • Fluorine Concept
  • CXO Concept
  • Weight Loss Drugs
  • Margin Trading & Securities Lending
  • High-Performance Stocks
  • Below IPO Price
  • Planned Share Reduction
  • Specialized, Refined, Differential and Innovative SMEs
  • Small-Cap ChiNext

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information